Relationship between De Ritis and clinical outcomes in patients with aneurysmal subarachnoid hemorrhage: Insights from the LongTEAM registry

doi:10.21203/rs.3.rs-4995063/v1

Download PDF

Article

Relationship between De Ritis and clinical outcomes in patients with aneurysmal subarachnoid hemorrhage: Insights from the LongTEAM registry

https://doi.org/10.21203/rs.3.rs-4995063/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

OBJECTIVE

Elevated aspartate aminotransferase-to-alanine aminotransferase ratio (De Ritis) has been associated with cardiovascular diseases and mortality. The clinical significance of De Ritis in the prognosis of hemorrhagic stroke has yet to be established. We aimed to investigate the associations between De Ritis levels and clinical outcomes in aneurysmal subarachnoid hemorrhage (aSAH).

METHODS

The authors retrospectively reviewed all aSAH patients admitted to their institution between January 2015 and September 2022 in the LongTEAM registry. Patients with aSAH were divided into four groups by quartiles of De Ritis, and two groups according to De Ritis < 1 and De Ritis ≥1. The functional outcomes at discharge and 90 days after discharge were assessed using the modified Rankin Scale (mRS). Multivariable logistic regression for poor functional outcome (mRS 3-6/4-6) and in-hospital complications were adopted to explore the associations between De Ritis and clinical outcomes. Furthermore, restricted cubic spline models were used to assess the dose-response relationships between De Ritis and clinical outcomes.

RESULTS

A total of 1,098 aSAH patients were included. The median De Ritis was 1.20 (interquartile range [IQR], 0.98-1.58). After adjusting for all the potential covariates and compared with those in the reference quartile, patients in the second De Ritis quartile had a lower risk of unfavorable functional outcome (both mRS 3-6 and mRS 4-6) at discharge assessment (OR 0.623, 95% CI 0.408-0.951; OR 0.547, 95% CI 0.318-0.943 respectively), patients in the second De Ritis quartile had a higher risk of MACE (OR 1.550, 95% CI 1.039-2.312), third quartile a higher risk of DCI (OR 1.569, 95%CI 1.047-2.353), and fourth quartile with a higher risk of anemia (OR 1.662, 95%CI 1.092-2.530). Furthermore, patients with higher levels of De Ritis had lower risk of hepatic function (Q2, Q3, and Q4) and disorder of lipoprotein metabolism (Q3 and Q4) in fully-adjusted models. Restricted cubic spline models showed a non-linear associations between De Ritis levels and risk of mRS 4-6 at discharge assessment, MACE, abnormal hepatic function, anemia and disorders of lipoprotein metabolism. There was no significant difference between the TAPS model (AUC: 0.801) and the TAPS plus De Ritis index model (AUC: 0.801) (P = 0.345). No improvement was observed (net reclassification improvement [NRI]: 0.0022 [-0.0409-0.0384], P= 0.9457; integrated discrimination improvement [IDI]: 0.0183 [-0.0008-0.0007], P = 0.8522). Similar associations were also observed when De Ritis ≥ 1 compared with De Ritis < 1. Similar findings were robust after excluding participants with De Ritis > 2.

CONCLUSIONS

Elevated De Ritis was associated with higher risk of unfavorable functional outcome at discharge, MACE, DCI and anemia. Given that postoperative De Ritis levels could help to identify high-risk patients with aSAH, these findings are of clinical relevance.

Health sciences/Diseases/Neurological disorders

Health sciences/Diseases/Neurological disorders/Cerebrovascular disorders

aspartate aminotransferase

alanine aminotransferase

aneurysmal subarachnoid hemorrhage

complications

outcomes

Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening condition with a high mortality rate of 50%, and even patients receiving optimal medical care may experience long-term disability.^1,2 As the global number of individuals who suffer new strokes, die, or remain disabled after a stroke increases, early identification of prognostic risk factors is crucial for targeted prevention.³

Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are commonly used to assess hepatic function in clinical practice. ALT is more liver-specific, while AST levels can rise due to ischemic cell death in various nonhepatic tissues such as the kidneys, heart, and brain. The AST to ALT ratio was first introduced by De Ritis et al. in 1957 to differentiate viral hepatitis from other icteric and anicteric hepatic diseases.⁴ Accumulating evidence suggests that an increased AST to ALT ratio (AAR, De Ritis) may serve as a surrogate marker for ischemic end-organ damage, correlating with higher rates of cardiovascular events and mortality.⁵ The underlying pathological effects of elevated De Ritis on cardiovascular organs include mitochondrial dysfunction and oxidative.^6,7

Since the De Ritis ratio has demonstrated prognostic value in various cancer entities, some research groups have explored its clinical significance in neurosurgical settings. Christoph Wetz et al. demonstrated that a high De Ritis ratio improved the prediction of progression-free survival after neuroendocrine tumor treatment but not during the treatment itself.^8-10 Pre-radiotherapy and postoperative De Ritis levels were revealed as novel serum prognosticators in newly diagnosed atypical meningiomas and glioblastomas, respectively.^11,12 In the neurovascular department, the De Ritis ratio may serve as a guide for intraoperative transfusion in unruptured intracranial aneurysm surgery.¹³ Furthermore, a dynamic fluctuation in the De Ritis ratio provided a significant independent prediction for mortality in patients with moderate-to-severe traumatic brain injuries.¹⁴

To our knowledge, no prior studies have considered using De Ritis to predict the prognosis of ruptured aneurysms or incorporated this ratio into an established risk model. However, the relationship between De Ritis and mortality, as well as long-term functional outcomes after aSAH, has not yet been sufficiently elucidated. This study aimed to explore the association between De Ritis and clinical outcomes after aSAH, including poor functional outcomes at discharge and 90 days, as well as in-hospital complications.

Study Design

We retrospectively reviewed the patient data from consecutive aSAH patients admitted to our institution between January 2015 and September 2022. All patient data were from the Long-term Prognosis of Emergency Aneurysmal Subarachnoid Hemorrhage (LongTEAM, ClinicalTrials.gov Identifier: NCT04785976) registry. This study was approved by the institutional review board of Beijing Tiantan Hospital. Informed consent for clinical analyses was obtained from all individual participants or their authorized representatives, and all the analyses were performed in accordance with the Declaration of Helsinki and the local ethics policies. Both procedures were performed by specific senior neurosurgeons, with an annual average of more than 300 procedures per neurosurgeon. All patients were managed according to the guidelines from the American Heart Association/American Stroke Association and institutional routine.

Inclusion and Exclusion Criteria

All patients had angiographically documented aSAH confirmed by CT or lumbar puncture. In this study, the inclusion criteria were 1) age ≥ 18 years; 2) emergency admission; 3) no previous aneurysm rupture; 4) only patients treated by surgical clipping or endovascular treatment; 5) less than 72 hours from rupture to admission and less than 72 hours from admission to treatment; 6) single aneurysm; and 7) complete 90-day follow-up. Exclusion criteria were 1) other neurological diseases (tumor, vascular malformation, Parkinson's disease, multiple sclerosis, and primary epilepsy) and functional or neurological deficit of the extremities due to any cause; 2) history of neurosurgery prior to rupture; and 3) treatment, including external ventricular drainage, intubation, and/or mechanical ventilation, at other hospitals before presentation to our hospital.

Data collection

Baseline clinical characteristics and imaging data were reviewed, such as age, sex, body mass index (BMI; calculated as weight in kilograms divided by the square of the height in meters, kg/m²), location of the ruptured aneurysm, intraventricular hemorrhage, acute hydrocephalus, and medical history (e.g. hypertension, diabetes mellitus, hyperlipidemia, stroke and heart disease). The World Federation of Neurosurgical Societies (WFNS) grade, modified Fisher Scale (mFS) grade, Graeb score, Subarachnoid Hemorrhage Early Brain Edema Score (SEBES), and modified Rankin Scale (mRS) score were assessed. Postoperative clinical complications during hospitalization were collected, including rebleeding, delayed cerebral ischemia (DCI), intracranial infection, stress ulcer bleeding, abnormal hepatic function, urinary tract infection (UTI), anemia, hypoproteinemia, pneumonia, and deep vein thrombosis (DVT), electrolyte disturbance, and disorders of lipoprotein metabolism. Supplemental Table 1 shows the detailed diagnostic criteria for in-hospital complications. The mRS score and mortality rate were collected at discharge.

Exposure

Fasting blood samples were collected within 24 hour of admission and the second morning after treatment routinely. Both preoperative and postoperative serum AST and ALT were tested immediately using standard methods at the laboratory. Laboratory tests including WBC (white blood cell), total protein (TP), albumin (ALB), globulin (GLB), total bilirubine (TBIL), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), apoprotein A1 (APO_A1), and apoprotein B (APO_B) were measured and documented. For normal tests values, please see the Supplementary Table 2.

De Ritis was calculated as AST divided by ALT. Participants were classified into four groups according to quartiles of De Ritis and two groups by the cut-off value of 1 according to previous studies. ^15,16 To mitigate surgical and endovascular interference, we designated postoperative De Ritis as the exposure variable.

Outcome Assessment

The primary outcome was the mRS (a stroke outcome scale with scores ranging from 0 [no symptoms] to 6 [dead]) score at discharge and 90 days after discharge. The certified clinical research coordinators and neurosurgeons followed up with patients via telephone or an outpatient appointment 90 days after discharge. Unfavorable outcome was defined as an mRS score of 3 to 6 or 4 to 6. Second outcomes were defined as presence of prespecified in-hospital complications.

Statistical Analysis

The descriptive statistics are summarized as median (interquartile range, IQR) for continuous variables with skewed distribution and frequency (percentage) for categorical variables. After testing for normality, continuous variables were analyzed using the nonparametric Mann-Whitney U test or Kruskal-Wallis test. The Pearson chi-square test, continuity correction test, or Fisher's exact test were used to test the dichotomized and categorical independent variables.

For poor functional outcome and in-hospital complications, the logistic regression model and OR with 95% CI was used. Patients with the lowest quartile of De Ritis or De Ritis < 1 were defined as the reference group. Three adjusted models were fitted. Model 1 adjusted for age (continuous) and sex. Model 2 further adjusted for BMI, current smoker, current alcohol drinking, medical history (hypertension, diabetes mellitus, dyslipidemia, stroke, heart disease), the WFNS, mFS score at admission, location of aneurysm and treatment modality. In model 3, laboratory tests including WBC (continuous), TC, TG, HDL, and LDL were further adjusted.¹⁶ Trend tests were performed using quartiles as ordinal variables. To assess the incremental predictive value of De Ritis in addition to conventional risk factors, Delong test, net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were applied. In addition, restricted cubic spline models were used to assess the dose-response relationships between De Ritis and clinical outcomes, and the knots were set at the lowest akaike information criterion (AIC) value for a better quality of model fitting.

To examine the robustness of our findings, we further did sensitivity analysis by excluding patients with De Ritis > 2, who may have underlying liver disease.

All statistical analyses were performed using R version 4.4.0 Statistical Software, GraphPad PRISM 8.3.0 (GraphPad Software Inc.) and validated by SPSS Statistics version 29.0 (IBM Corp.). Statistical significance was set at a two-tailed P < 0.05.

Data Availability

All relevant data that support the findings of this study are within the paper or its supplementary material.

Patient Characteristics

After exclusion of 170 ineligible patients, a total of 1,098 patients in the LongTEAM cohort who had their hospitalization between January 2015 and September 2022 were enrolled in the present study. The baseline characteristics between the included patients and those excluded are presented in Supplemental Table 3. Patients excluded from the current study were more less likely to be smoker, alcohol drinker, had lower proportion of diseases history (such as hypertension, hyperlipidemia, history of stroke, and onset-loss of consciousness).

Among the 1,098 patients, the median age was 55 years (IQR, 48 to 63), 58.5% were female, 24.6% were current smoker, and 18.4% were current alcohol drinkers. The median De Ritis was 1.20 (IQR, 0.89 to 1.58). The demographics and clinical characteristics of the study population are shown in Table 1. As compared to patients with the lowest De Ritis quartile, those with higher De Ritis level were older, more likely to be women, with loss of consciousness, WFNS 4-5, and underwent surgical clipping treatment, less likely to be obesity, current smokers or drinkers. Moreover, patients with higher De Ritis level had high postoperative HDL and AST concentration, but lower preoperative ALT, AST, postoperative total protein, albumin, TG, LDL, AST, Apoprotein A1 and Apoprotein B concentration.

De Ritis and functional outcomes

At discharge assessment, there were 446 (40.6%) patients with mRS 3-6, 234 (21.3%) patients with mRS 4-6, and 17 (1.5%) had died. During the 3 months assessment, there were 210 (19.1%) patients with mRS 3-6, 131 (11.9%) patients with mRS 4-6, and 28 (2.6%) had died (Table 2).

After adjusting for all the potential covariates (Model 3), patients in the second De Ritis quartile had a lower risk of unfavorable functional outcome (both mRS 3-6 and mRS 4-6) at discharge assessment (OR 0.623, 95% CI 0.408-0.951; OR 0.547, 95% CI 0.318-0.943 respectively), compared with those in the reference quartile. We also observed increased risks of mRS 3-6 and mRS 4-6 at 90 days for patients in the fourth De Ritis quartile in age and sex adjusted model, but the risks were attenuated and became insignificant after adjusted all covariates. We also observed a significant linear association between De Ritis and death at both discharge and 90 days (P for trend = 0.018, P for trend = 0.016, respectively) after adjusted for all covariates.

Restricted cubic spline models showed a non-linear associations between De Ritis levels and risk of mRS 4-6 at discharge assessment (Table 3, Fig. 1A). However, for mRS 3-6 and death at discharge and 90 days assessment, the RCS model failed to reach statistical significance (Fig. 1B).

Incremental effect of De Ritis in predicting 90 days unfavorable outcomes

In an analysis of 90 days unfavorable outcomes (mRS 3-6), ROC curves were constructed to assess the predictive ability of the TAPS prognostic model¹⁷ and the TAPS model plus De Ritis index respectively. There was no significant difference between the TAPS model (AUC: 0.801) and the De Ritis index model (AUC: 0.801) (P = 0.345). No improvement was observed in the predictive power of the TAPS model by incorporating the De Ritis index in patients with aSAH (net reclassification improvement [NRI]: 0.0022 [-0.0409-0.0384], P = 0.9457; integrated discrimination improvement [IDI]: 0.0183 [-0.0008-0.0007], P = 0.8522).

De Ritis and in-hospital complications

The three most prevalent in-hospital complications were electrolyte disturbance (813/1098 [74.0%]), hypoproteinemia (403/1098 [36.7%]), and MACE (392/1098 [35.7%]).

After adjusting for all the potential covariates (Model 3), patients in the second De Ritis quartile had a higher risk of MACE (OR 1.550, 95% CI 1.039-2.312), and third quartile a higher risk of DCI (OR 1.569, 95%CI 1.047-2.353), and fourth quartile with a higher risk of anemia (OR 1.662, 95%CI 1.092-2.530), compared with those in the reference quartile. Furthermore, patients with higher levels of De Ritis had lower risk of hepatic function (Q2, Q3, and Q4) and disorder of lipoprotein metabolism (Q3 and Q4) in fully-adjusted models. We found that the risk of anemia was significantly increased with increasing De Ritis (P for trend = 0.017).

Restricted cubic spline models showed a non-linear associations between De Ritis levels and risk of MACE (knot = 5), abnormal hepatic function (knot = 6), anemia (knot = 5) and disorders of lipoprotein metabolism (knot = 3, Table 3, Fig. 1C-1F). However, no other in-hospital complications showed statistical significance.

Sensitivity analysis

When patients were classified into two groups, those with De Ritis ≥ 1 had a higher risk of anemia (aOR 1.457, 95%CI 1.070-2.031, Table 4) and a lower risk of abnormal hepatic function (aOR 0.596, 95%CI 0.434-0.818) and disorders of lipoprotein metabolism (aOR 0.722, 95%CI 0.523-0.997), consistent with the findings with quartiles. Similar findings were robust after excluding participants with De Ritis > 2 in sensitivity analysis (Table S4 and Table S5).

The primary finding of the current study conducted within the LongTEAM registry was that elevated De Ritis levels were associated with an increased risk of unfavorable functional outcomes at discharge and several in-hospital complications in patients with aSAH. These associations persisted even after full adjustment for potential confounders. However, there was no supplementary incremental performance of De Ritis for the aSAH prognostic TAPS model.

Large aSAH cohort studies have demonstrated worse clinical outcomes in patients with chronic liver disease compared to those without, and a higher Model for End-Stage Liver Disease score in aSAH patients was linked to an increased risk of mortality.^18,19 De Ritis serves as a readily available non-invasive marker of hepatocellular damage and liver disease.²⁰ Recent studies have indicated that an association of De Ritis ratio with an increased risk of cardiovascular diseases, such as acute type A aortic dissection,²¹ acute heart failure,²² acute ischemic stroke,²³ and other cardiovascular diseases. Furthermore, several large clinical studies have reported that an elevated De Ritis ratio was independently associated with an unfavorable prognosis and mortality, even after adjusting for other well-established vascular risk factors.^24-26 Consistent with previous findings that increased De Ritis is associated with worse functional outcomes, our results indicated a positive correlation between De Ritis and higher mortality rates in aSAH patients (P for trend = 0.016).

There is substantial evidence that liver enzymes play a crucial biological role in coronary artery calcification, endothelial dysfunction, and metabolic disorders, all of which are critical determinants of clinical outcomes in stroke.²⁷ Chun-On Lee conducted a National Health and Nutrition Examination Survey from 1999 to 2016 and found that while liver fat score was not associated with myocardial infarction or stroke, it was linked to increased all-cause and cardiovascular mortality, with hazard ratios (HRs) of 1.10 (95% CI: 1.07-1.13) (p < 0.001) and 1.12 (95% CI: 1.06-1.17) (p < 0.001), respectively.²⁷ However, to the best of our knowledge, no study has assessed the association between De Ritis and the prognosis of hemorrhagic stroke. In our study of 1,098 patients, a higher postoperative De Ritis ratio was associated with poor functional outcomes (defined as mRS 3-6) at discharge. We also observed a non-marginal significance at 3 months in the fully adjusted model (P = 0.398). The discrepancy with previous results from ischemic stroke may be due to short-term strong prognostic factors overshadowing the role of De Ritis. Several plausible explanations exist for the association between De Ritis and poor outcomes after aSAH. First, postoperative complications such as MACE, DCI, and anemia are significant, and De Ritis can predict these events to some extent. Second, previous studies have found that excessive glutamate is released from neurons into the brain parenchyma extracellular space after a stroke. A small increase in glutamate concentration in the cerebrospinal fluid can cause a pronounced increase in intracellular calcium and trigger neuronal death. Therefore, glutamate is associated with greater stroke severity, larger infarct volume, and worse functional outcomes. Although the direct roles of ALT and AST in the regulation of glutamate are less known, the increase in CSF glutamine may result from increased activity of aspartate aminotransferase, an enzyme that forms glutamine, in the pathological brain.²⁸ High glutamate levels within the lesion, monitored by cerebral microdialysis, are linked to a greater likelihood of DCI occurrence.²⁹ In our study, we discovered that the third quartile of the De Ritis ratio independently correlated with DCI, even after adjusting for other significant predictors, indirectly aiding in the early management of 3-month mRS in patients. Third, our results indicated a statistical relevance between the second quartile of De Ritis and postoperative MACE, as well as a nonlinear relationship. These findings are clinically significant because aSAH patients at increased risk of MACE could be identified using the easily accessible and limited threshold of the aminotransferase ratio.

Given that the liver receives nearly a quarter of the total cardiac output, the relevance of De Ritis to systemic blood flow changes is logical and it responds swiftly. Recent studies have demonstrated that De Ritis has a strong prognostic role in predicting both CVD incidence and cardiovascular mortality over more than a decade of follow-up in large cohorts from European and Asian populations.^30,31 De Ritis is noted as a potent predictive and indicative biomarker of metabolic syndrome.³² Our study suggests that the smaller the AST to ALT ratio, the more pronounced the disorders of lipoprotein metabolism. In cases positive for metabolic syndrome, the De Ritis ratio tends to be lower, consistent with previous studies.³³ Further research is needed to investigate the potential of these biomarkers and their appropriate reference values to more accurately predict aSAH population risks, which may be particularly valuable for risk stratification.

The primary strength of our study lies in its extensive aSAH registry, comprising over 1,000 participants, providing ample statistical power. To mitigate the influence of outliers, we excluded patients with a De Ritis ratio greater than 2 and discovered similar conclusions. Additionally, for practical clinical application, we calculated the study results with a critical value of 1, arriving at the same conclusion.

Limitations

Our study should be considered in light of certain limitations. First, the De Ritis index was not initially developed for cerebrovascular disorder populations. We emphasize the prognostic role of asymptomatic elevation of De Ritis among stroke patients with suspected lipoprotein disorder risks. Second, the specific threshold of De Ritis contributing to adverse outcomes after aSAH requires further validation. Although many covariates were adjusted in this study, the possibility of residual confounding cannot be ruled out. Additionally, since repeated measurements of De Ritis were unavailable, we cannot conclude the cumulative and causal relationship between De Ritis and clinical outcomes of aSAH. Third, this study cohort was derived from a single center in China, potentially limiting the applicability of the findings to other ethnic groups or populations with different medical systems. Fourth, only a 90-day follow-up was considered in the analysis; longer-term outcomes related to De Ritis should be investigated in the future.

In patients with aSAH, elevated De Ritis levels were correlated with an increased risk of unfavorable functional outcomes at discharge, MACE, DCI, and anemia. Recognizing that postoperative De Ritis levels may aid in identifying high-risk aSAH patients, these findings hold significant clinical relevance.

Acknowledgments

This study was supported by the National Key Research and Development Program of China (Grant no. 2021YFC2501101).

Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: Population-based study and systematic review. Neurology. May 11 2010;74(19):1494-501. doi:10.1212/WNL.0b013e3181dd42b3
Ma Q, Li R, Wang L, et al. Temporal trend and attributable risk factors of stroke burden in China, 1990-2019: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. Dec 2021;6(12):e897-e906. doi:10.1016/S2468-2667(21)00228-0
Liu Q, Li K, He H, et al. The markers and risk stratification model of intracranial aneurysm instability in a large Chinese cohort. Sci Bull (Beijing). Jun 15 2023;68(11):1162-1175. doi:10.1016/j.scib.2023.05.001
De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. Feb 1957;2(1):70-4. doi:10.1016/0009-8981(57)90027-x
Zoppini G, Cacciatori V, Negri C, et al. The aspartate aminotransferase-to-alanine aminotransferase ratio predicts all-cause and cardiovascular mortality in patients with type 2 diabetes. Medicine (Baltimore). Oct 2016;95(43):e4821. doi:10.1097/MD.0000000000004821
Nickovic VP, Miric D, Kisic B, et al. Oxidative stress, NOx/l-arginine ratio and glutathione/glutathione S-transferase ratio as predictors of 'sterile inflammation' in patients with alcoholic cirrhosis and hepatorenal syndrome type II. Ren Fail. Nov 2018;40(1):340-349. doi:10.1080/0886022X.2018.1459699
Kurhaluk N, Tkachenko H, Lukash O. Melatonin modulates oxidative phosphorylation, hepatic and kidney autophagy-caused subclinical endotoxemia and acute ethanol-induced oxidative stress. Chronobiol Int. Dec 2020;37(12):1709-1724. doi:10.1080/07420528.2020.1830792
Ruhwedel T, Rogasch JMM, Huang K, et al. The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. Cancers (Basel). Feb 5 2021;13(4)doi:10.3390/cancers13040635
Galler M, Rogasch JMM, Huang K, et al. Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [(177)Lu]Lu-DOTATOC. Cancers (Basel). Mar 31 2022;14(7)doi:10.3390/cancers14071768
Wetz C, Ruhwedel T, Schatka I, et al. Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. Cancers (Basel). Dec 6 2023;15(24)doi:10.3390/cancers15245717
Chang WI, Byun HK, Lee JH, et al. Novel Postoperative Serum Biomarkers in Atypical Meningiomas: A Multicenter Study. Neurosurgery. Sep 1 2023;93(3):599-610. doi:10.1227/neu.0000000000002457
Kim J, Lee HI, Kim IA, et al. De Ritis ratio in elderly glioblastoma patients treated with chemoradiation: A comprehensive analysis of serum biomarkers. Neurooncol Adv. Jan-Dec 2024;6(1):vdad173. doi:10.1093/noajnl/vdad173
Sim JH, Kim CS, Ha S, Kim H, Park YS, Kim JU. Association between De Ritis ratio and intraoperative blood transfusion in patients undergoing surgical clipping of unruptured intracranial aneurysms: a single center, retrospective, propensity score-matched study. Korean J Anesthesiol. Apr 2024;77(2):246-254. doi:10.4097/kja.23415
Tsai CH, Rau CS, Chou SE, Su WT, Hsu SY, Hsieh CH. Delta De Ritis Ratio Is Associated with Worse Mortality Outcomes in Adult Trauma Patients with Moderate-to-Severe Traumatic Brain Injuries. Diagnostics (Basel). Dec 1 2022;12(12)doi:10.3390/diagnostics12123004
Durak K, Nubbemeyer K, Zayat R, et al. De Ritis Ratio to Predict Clinical Outcomes of Intermediate- and High-Risk Pulmonary Embolisms. J Clin Med. Apr 4 2024;13(7)doi:10.3390/jcm13072104
Xu Q, Zhang X, Li H, et al. Aspartate aminotransferase to alanine aminotransferase ratio and clinical outcomes after acute ischemic stroke: the CNSR-III registry. Intern Emerg Med. Oct 2022;17(7):1987-1996. doi:10.1007/s11739-022-03059-w
Li R, Lin F, Chen Y, et al. A 90-Day Prognostic Model Based on the Early Brain Injury Indicators after Aneurysmal Subarachnoid Hemorrhage: the TAPS Score. Transl Stroke Res. Apr 2023;14(2):200-210. doi:10.1007/s12975-022-01033-4
Zhang Y, Li L, Jia L, et al. Association of Chronic Liver Disease and Mortality in Patients With Aneurysmal Subarachnoid Hemorrhage. Stroke. Oct 2021;52(10):e614-e617. doi:10.1161/STROKEAHA.121.034136
Li T, Wang P, Gong X, et al. Prevalence and Prognostic Significance of Liver Fibrosis in Patients With Aneurysmal Subarachnoid Hemorrhage. Front Neurol. 2022;13:850405. doi:10.3389/fneur.2022.850405
Giannini E, Botta F, Testa E, et al. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. Am J Gastroenterol. Nov 2002;97(11):2855-60. doi:10.1111/j.1572-0241.2002.07053.x
Liu H, Li H, Han L, et al. Inflammatory risk stratification individualizes anti-inflammatory pharmacotherapy for acute type A aortic dissection. Innovation (Camb). Jul 10 2023;4(4):100448. doi:10.1016/j.xinn.2023.100448
Biegus J, Hillege HL, Postmus D, et al. Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. Eur J Heart Fail. Jul 2016;18(7):830-9. doi:10.1002/ejhf.532
Ahmadabad MA, Naeimi A, Keymoradzadeh A, et al. Evaluation of De Ritis (AST/ALT), ALP/ALT, and AST/ALP ratios as prognostic factors in patients with acute ischemic stroke. BMC Neurol. Dec 3 2022;22(1):450. doi:10.1186/s12883-022-02989-4
Lv D, Guo Y, Li X, Zhang L. Increased transferase ratio is associated with adverse cardio-cerebral events in patients with unstable angina: A retrospective cohort study. Medicine (Baltimore). Aug 4 2023;102(31):e34563. doi:10.1097/MD.0000000000034563
Liu X, Liu P. Elevated AST/ALT ratio is associated with all-cause mortality in patients with stable coronary artery disease: a secondary analysis based on a retrospective cohort study. Sci Rep. Jun 2 2022;12(1):9231. doi:10.1038/s41598-022-13355-2
Wang L, Xu Y, Zhang S, Bibi A, Xu Y, Li T. The AST/ALT Ratio (De Ritis Ratio) Represents an Unfavorable Prognosis in Patients in Early-Stage SFTS: An Observational Cohort Study. Front Cell Infect Microbiol. 2022;12:725642. doi:10.3389/fcimb.2022.725642
Lee CO, Li HL, Tsoi MF, Cheung CL, Cheung BMY. Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999-2016. Ann Med. Dec 2021;53(1):1065-1073. doi:10.1080/07853890.2021.1943514
D'Aniello A, Fisher G, Migliaccio N, Cammisa G, D'Aniello E, Spinelli P. Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients. Neurosci Lett. Nov 4 2005;388(1):49-53. doi:10.1016/j.neulet.2005.06.030
Tholance Y, Aboudhiaf S, Balanca B, et al. Early brain metabolic disturbances associated with delayed cerebral ischemia in patients with severe subarachnoid hemorrhage. J Cereb Blood Flow Metab. Nov 2023;43(11):1967-1982. doi:10.1177/0271678X231193661
Weng SF, Kai J, Guha IN, Qureshi N. The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment. Open Heart. 2015;2(1):e000272. doi:10.1136/openhrt-2015-000272
Yokoyama M, Watanabe T, Otaki Y, et al. Association of the Aspartate Aminotransferase to Alanine Aminotransferase Ratio with BNP Level and Cardiovascular Mortality in the General Population: The Yamagata Study 10-Year Follow-Up. Dis Markers. 2016;2016:4857917. doi:10.1155/2016/4857917
Yadav D, Choi E, Ahn SV, et al. Incremental Predictive Value of Serum AST-to-ALT Ratio for Incident Metabolic Syndrome: The ARIRANG Study. PLoS One. 2016;11(8):e0161304. doi:10.1371/journal.pone.0161304
Oye-Somefun A, Kuk JL, Ardern CI. Associations between elevated kidney and liver biomarker ratios, metabolic syndrome and all-cause and coronary heart disease (CHD) mortality: analysis of the U.S. National Health and Nutrition Examination Survey (NHANES). BMC Cardiovasc Disord. Jul 26 2021;21(1):352. doi:10.1186/s12872-021-02160-w

Table 1. Baseline characteristics according to quartiles of De Ritis.
Characteristics	Total	Quartiles of De Ritis				P value
Characteristics	Total	Q1 (<0.89)	Q2 (0.89 to <1.20)	Q3 (1.20 to <1.58)	Q4 (≥1.58)	P value
No. of the patients	1098	271	272	280	275
De Ritis, median (IQR)	1.20 (0.89-1.58)	0.70 (0.59-0.81)	1.05 (0.97-1.12)	1.35 (1.27-1.45)	1.92 (1.71-2.29)	<0.001
Age, median (IQR), y	55 (48-63)	51 (45-59)	55 (48-63)	58 (50-65)	56 (49-64)	<0.001
Age > 55 years old, n (%)	532 (48.5)	97 (35.8)	126 (46.3)	165 (58.9)	144 (52.4)	<0.001
BMI, median (IQR), kg/m^2	24.65 (22.83-27.06)	25.39 (23.44-27.91)	25.29 (23.18-27.92)	24.22 (22.55-26.12)	24.22 (22.33-26.04)	<0.001
Female, n (%)	646 (58.8)	136 (50.2)	165 (60.7)	178 (63.6)	167 (60.7)	0.008
Current smoking, n (%)	272 (24.8)	83 (30.6)	68 (25.0)	69 (24.6)	52 (18.9)	0.018
Current alcohol drinking, n (%)	202 (18.4)	64 (23.6)	48 (17.6)	51 (18.2)	39 (14.2)	0.041
Medical History, n (%)
Hypertension	642 (58.5)	158 (58.3)	175 (64.3)	164 (58.6)	145 (52.7)	0.055
Diabetes mellitus	95 (8.7)	30 (11.1)	24 (8.8)	22 (7.9)	19 (6.9)	0.348
Hyperlipidemia	81 (7.4)	23 (8.5)	27 (9.9)	17 (6.1)	14 (5.1)	0.118
Stroke	88 (8.0)	19 (7.0)	23 (8.5)	25 (8.9)	21 (7.6)	0.846
Heart diseases	191 (17.4)	50 (18.5)	48 (17.6)	48 (17.1)	45 (16.4)	0.932
Admission status
Loss of consciousness, n (%)	337 (30.7)	71 (26.2)	73 (26.8)	89 (31.8)	104 (37.8)	0.011
WFNS 4-5, n (%)	244 (22.2)	40 (14.8)	53 (19.5)	67 (23.9)	84 (30.5)	<0.001
mFS 3-4, n (%)	775 (69.8)	184 (67.9)	181 (66.5)	212 (75.7)	198 (72.0)	0.075
Hydrocephalus, n (%)	431 (39.3)	108 (39.9)	99 (36.4)	117 (41.8)	107 (38.9)	0.628
Graeb score 5-12, n (%)	90 (8.2)	13 (4.8)	24 (8.8)	24 (8.6)	29 (10.5)	0.095
SEBES 3-4, n (%)	522 (47.5)	125 (46.1)	125 (46.0)	137 (48.9)	135 (49.1)	0.808
Aneurysm at posterior circulation, n (%)	114 (10.4)	27 (10.0)	35 (12.9)	31 (11.1)	21 (7.6)	0.238
Surgical clipping, n (%)	582 (53.0)	122 (45.0)	134 (49.3)	134 (47.9)	192 (69.8)	<0.001
Laboratory data, median (IQR)
Preoperative WBC	12.43 (9.91-15.41)	12.25 (9.95-15.51)	12.53 (10.11-15.50)	12.37 (9.90-15.30)	12.54 (9.59-15.54)	0.634
Preoperative WBC >11.28, n (%)	673 (61.3)	160 (59.0)	177 (65.1)	164 (58.6)	172 (62.5)	0.351
Preoperative ALT, IU/L	18.40 (13.50-26.70)	31.00 (22.20-43.35)	19.60 (15.10-26.00)	15.25 (12.65-19.65)	14.00 (10.8-18.35)	<0.001
Preoperative AST, IU/L	20.60 (16.60-27.00)	22.80 (17.65-31.00)	20.30 (16.00-25.00)	19.40 (16.00-23.95)	20.00 (17.00-27.00)	<0.001
Total Protein, g/L	65.90 (61.40-70.40)	67.80 (63.70-71.45)	66.85 (62.50-71.50)	65.10 (61.45-69.50)	63.00 (58.05-68.45)	<0.001
Albumin, g/L	39.10 (35.90-42.00)	40.70 (37.90-43.10)	39.70 (36.75-42.50)	38.75 (35.70-41.30)	36.90 (33.75-39.85)	<0.001
Globulin, g/L	26.65 (24.00-29.40)	26.70 (24.40-29.65)	27.00 (24.10-29.55)	26.55 (23.90-29.30)	26.40 (23.45-28.85)	0.184
Total bilirubine, μmol/L	14.30 (11.28-19.20)	14.80 (11.50-19.35)	14.00 (11.45-19.00)	14.05 (11.10-19.15)	14.60 (11.05-19.10)	0.802
Total cholesterol, mmol/L	4.44 (3.85-5.15)	4.54 (3.99-5.27)	4.44 (3.90-5.16)	4.42 (3.88-5.13)	4.35 (3.77-5.08)	0.124
Triglyceride, mmol/L	1.14 (0.85-1.57)	1.23 (0.95-1.77)	1.14 (0.87-1.69)	1.13 (0.85-1.46)	0.99 (0.76-1.41)	<0.001
HDL, mmol/L	1.30 (1.10-1.55)	1.26 (1.07-1.50)	1.28 (1.11-1.52)	1.30 (1.09-1.57)	1.37 (1.19-1.61)	0.001
LDL, mmol/L	2.59 (2.03-3.20)	2.75 (2.14-3.45)	2.65 (2.09-3.25)	2.57 (2.03-3.20)	2.38 (1.86-3.02)	<0.001
ALT, IU/L	16.00 (11.90-22.80)	26.00 (18.45-34.855)	15.95 (13.00-19.65)	13.00 (10.50-17.25)	13.00 (10.00-17.60)	<0.001
AST, IU/L	18.40 (14.20-26.33)	17.00 (13.50-22.35)	16.55 (13.20-20.25)	17.35 (14.00-23.60)	26.30 (19.10-37.55)	<0.001
Apoprotein A1, g/L	1.24 (1.06-1.45)	1.26 (1.08-1.46)	1.27 (1.11-1.45)	1.24 (1.09-1.48)	1.19 (1.00-1.39)	0.007
Apoprotein B, g/L	0.91 (0.77-1.08)	0.94 (0.81-1.14)	0.92 (0.78-1.11)	0.92 (0.78-1.09)	0.88 (0.73-1.03)	<0.001
IQR interquartile range; BMI body mass index; WFNS World Federation of Neurological Societies Scale; mFS modified Fisher Scale; SEBES Subarachnoid Hemorrhage Early Brain Edema Score; AST aspartate aminotransferase; ALT alanine aminotransferase; De Ritis AST/ALT ratio; HDL high-density lipoprotein; LDL low-density lipoprotein.

Table 2. Associations of De Ritis with poor functional outcomes at discharge and 3 months follow-up.
Outcomes	Total n = 1098	Quartiles of De Ritis				P for trend	Binary classification
Outcomes	Total n = 1098	Q1 n = 271	Q2 n = 272	Q3 n = 280	Q4 n = 275	P for trend	<1 n = 360	≥1 n =738
Death at discharge
n (%)	17 (1.5)	0 (0)	2 (0.7)	4 (1.4)	11 (4.0)		2 (0.6)	15 (2.0)
Unadjusted		Ref.	-	-	-	<0.001	Ref.	3.729 (0.848-16.396)
Model 1		Ref.	-	-	-	<0.001	Ref.	1.184 (0.904-1.552)
Model 2		Ref.	-	-	-	0.018	Ref.	1.903 (0.374-9.674)
Model 3		Ref.	-	-	-	0.018	Ref.	1.912 (0.358-10.203)
mRS 3-6 at discharge
n (%)	446 (40.6)	100 (36.9)	93 (34.2)	129 (46.1)	124 (45.1)		127 (35.3)	319 (43.2)
Unadjusted		Ref.	0.888 (0.625-1.263)	1.461 (1.039-2.054)	1.404 (0.997-1.978)	0.010	Ref.	1.382 (1.065-1.792)
Model 1		Ref.	0.782 (0.545-1.124)	1.181 (0.828-1.685)	1.187 (0.832-1.693)	0.112	Ref.	1.354 (0.973-1.885)
Model 2		Ref.	0.646 (0.424-0.983)	1.012 (0.671-1.526)	0.761 (0.497-1.165)	0.505	Ref.	0.900 (0.654-1.237)
Model 3		Ref.	0.623 (0.408-0.951)	0.993 (0.656-1.502)	0.747 (0.483-1.155)	0.482	Ref.	0.884 (0.641-1.220)
mRS 4-6 at discharge
n (%)	234 (21.3)	49 (18.1)	43 (15.8)	68 (24.3)	74 (26.9)		61 (16.9)	173 (23.4)
Unadjusted		Ref.	0.851 (0.543-1.333)	1.453 (0.962-2.196)	1.668 (1.109-2.509)	0.002	Ref.	1.468 (1.064-2.027)
Model 1		Ref.	0.809 (0.513-1.276)	1.311 (0.857-2.006)	1.537 (1.012-2.336)	0.008	Ref.	1.354 (0.973-1.885)
Model 2		Ref.	0.596 (0.348-1.021)	1.043 (0.631-1.724)	0.893 (0.536-1.489)	0.828	Ref.	0.954 (0.640-1.423)
Model 3		Ref.	0.547 (0.318-0.943)	1.006 (0.606-1.670)	0.819 (0.484-1.385)	0.991	Ref.	0.895 (0.597-1.343)
Death at 90 days
n (%)	28 (2.6)	1 (0.4)	3 (1.1)	7 (2.5)	17 (6.2)		3 (0.8)	25 (3.4)
Unadjusted		Ref.	3.011 (0.311-29.130)	6.923 (0.846-56.650)	17.791 (2.351-134.649)	<0.001	Ref.	4.190 (1.257-13.971)
Model 1		Ref.	2.744 (0.283-26.650)	5.871 (0.709-48.596)	15.639 (2.051-119.219)	<0.001	Ref.	3.697 (1.098-12.447)
Model 2		Ref.	1.878 (0.182-19.332)	4.224 (0.487-36.609)	7.230 (0.895-58.368)	0.008	Ref.	2.004 (0.556-7.227)
Model 3		Ref.	1.915 (0.183-20.006)	4.317 (0.491-37.954)	6.679 (0.812-54.919)	0.016	Ref.	1.787 (0.487-6.560)
mRS 3-6 at 90 days
n (%)	210 (19.1)	33 (12.2)	45 (16.5)	62 (22.1)	70 (25.5)		49 (13.6)	161 (21.8)
Unadjusted		Ref.	1.430 (0.881-2.321)	2.051 (1.294-3.251)	2.463 (1.564-3.878)	<0.001	Ref.	1.780 (1.256-2.521)
Model 1		Ref.	1.260 (0.769-2.067)	1.608 (0.999-2.588)	2.045 (1.282-3.261)	<0.001	Ref.	1.486 (1.038-2.128)
Model 2		Ref.	1.116 (0.645-1.931)	1.436 (0.848-2.432)	1.401 (0.826-2.378)	0.180	Ref.	1.175 (0.782-1.766)
Model 3		Ref.	1.035 (0.594-1.803)	1.371 (0.805-2.335)	1.223 (0.710-2.109)	0.398	Ref.	1.072 (0.708-1.624)
mRS 4-6 at 90 days
n (%)	131 (11.9)	15 (5.5)	29 (10.7)	40 (14.3)	47 (17.1)		27 (7.5)	104 (14.1)
Unadjusted		Ref.	2.037 (1.066-3.892)	2.844 (1.532-5.282)	3.518 (1.915-6.462)	<0.001	Ref.	2.032 (1.304-3.167)
Model 1		Ref.	1.737 (0.901-3.352)	2.101 (1.115-3.959)	2.792 (1.502-5.190)	<0.001	Ref.	1.627 (1.032-2.564)
Model 2		Ref.	1.537 (0.759-3.112)	1.851 (0.934-3.668)	1.867 (0.945-3.688)	0.103	Ref.	1.237 (0.746-2.051)
Model 3		Ref.	1.456 (0.716-2.962)	1.731 (0.870-3.446)	1.678 (0.837-3.361)	0.196	Ref.	1.107 (0.662-1.851)

ORs with 95% CIs were calculated using Logistic regression model.

Model 1: adjusted for age (continuous variable) and sex.

Model 2: adjusted for variables in model 1, body mass index, current smoking, current alcohol drinking, medical history (hypertension, diabetes mellitus, dyslipidemia, stroke, heart disease), WFNS , mFS, aneurysm location and treatment modality.

Model 3: adjusted for variables in model 2, plus preoperative WBC count, total cholesterol, triglyceride, high-density lipoprotein, and low-density lipoprotein.

Bold indicate statistical significance.

WFNS World Federation of Neurological Societies Scale; mFS modified Fisher Scale; WBC white blood cell; mRS modified Rankin Scale;

Table 3. Associations of De Ritis with poor functional outcomes at discharge and 3 months follow-up.
Outcomes	P = 0.1			P = 0.5
Outcomes	knot	p-overall	p-non-linear	knot	p-overall	p-non-linear
Death at discharge	-	-	-	-	-	-
mRS 3-6 at discharge	7	0.173	0.118	7	0.173	0.118
mRS 4-6 at discharge	7	0.060	0.041	7	0.060	0.041
Death at 90 days	4	0.099	0.182	4	0.099	0.182
mRS 3-6 at 90 days	3	0.356	0.748	3	0.356	0.748
mRS 4-6 at 90 days	3	0.319	0.706	3	0.319	0.706
Intracranial infection	3	0.300	0.130	3	0.300	0.130
MACE	5	0.004	0.002	5	0.004	0.002
Stress ulcer bleeding	3	0.642	0.368	3	0.642	0.368
Abnormal hepatic function	6	0.002	0.008	6	0.002	0.008
UTI	3	0.900	0.881	3	0.900	0.881
Anemia	5	0.032	0.036	5	0.032	0.036
Hypoproteinemia	3	0.281	0.839	3	0.281	0.839
Pneumonia	3	0.336	0.229	3	0.336	0.229
DVT	3	0.162	0.065	3	0.162	0.065
Electrolyte disturbance	3	0.182	0.527	3	0.182	0.527
Disorders of lipoprotein metabolism	3	0.006	0.030	3	0.006	0.030
DCI	6	0.133	0.114	6	0.133	0.114

mRS modified Rankin Scale; MACE major adverse cardiac event; UTI urinary tract infection; DVT deep venous thrombosis; DCI delayed cerebral ischemia;

Table 4. Associations of De Ritis with in-hospital complications.
Outcomes	Total n = 1098	Quartiles of De Ritis				P for trend	Binary classification
Outcomes	Total n = 1098	Q1 n = 271	Q2 n = 272	Q3 n = 280	Q4 n = 275	P for trend	<1 n = 360	≥1 n =738
Intracranial infection
n (%)	142 (12.9)	29 (10.7)	24 (8.8)	41 (14.6)	48 (17.5)		37 (10.3)	105 (14.2)
Unadjusted		Ref.	0.808 (0.457-1.427)	1.432 (0.861-2.379)	1.765 (1.075-2.896)	0.004	Ref.	1.397 (0.941-2.073)
Model 1		Ref.	0.849 (0.478-1.508)	1.531 (0.909-2.579)	1.864 (1.124-3.089)	0.003	Ref.	1.446 (0.966-2.164)
Model 2		Ref.	0.704 (0.382-1.297)	1.287 (0.728-2.276)	1.058 (0.609-1.837)	0.499	Ref.	0.973 (0.626-1.514)
Model 3		Ref.	0.695 (0.377-1.281)	1.292 (0.728-2.294)	1.070 (0.608-1.882)	0.472	Ref.	0.968 (0.619-1.513)
MACE
n (%)	392 (35.7)	91 (33.6)	112 (41.2)	113 (40.4)	76 (27.6)		129 (35.8)	263 (35.6)
Unadjusted		Ref.	1.385 (0.977-1.963)	1.338 (0.946-1.894)	0.755 (0.524-1.088)	0.060	Ref.	0.998 (0.767-1.298)
Model 1		Ref.	1.269 (0.889-1.812)	1.125 (0.786-1.612)	0.647 (0.444-0.942)	0.006	Ref.	0.872 (0.664-1.144)
Model 2		Ref.	1.529 (1.028-2.275)	1.356 (0.904-2.034)	0.806 (0.521-1.246)	0.160	Ref.	1.097 (0.803-1.498)
Model 3		Ref.	1.550 (1.039-2.312)	1.415 (0.938-2.133)	0.814 (0.522-1.269)	0.189	Ref.	1.135 (0.827-1.556)
Stress ulcer bleeding
n (%)	239 (21.8)	91 (33.6)	112 (41.2)	113 (40.4)	76 (27.6)		81 (22.5)	158 (21.4)
Unadjusted		Ref.	0.856 (0.570-1.286)	1.186 (0.805-1.747)	0.663 (0.434-1.013)	0.118	Ref.	0.943 (0.696-1.278)
Model 1		Ref.	0.793 (0.525-1.199)	1.031 (0.691-1.537)	0.587 (0.380-0.905)	0.032	Ref.	0.847 (0.620-1.158)
Model 2		Ref.	0.810 (0.526-1.248)	1.076 (0.706-1.640)	0.639 (0.400-1.020)	0.111	Ref.	0.925 (0.662-1.292)
Model 3		Ref.	0.836 (0.541-1.291)	1.141 (0.744-1.748)	0.684 (0.425-1.101)	0.203	Ref.	0.980 (0.698-1.375)
Abnormal hepatic funciton
n (%)	293 (26.7)	92 (33.9)	66 (24.3)	72 (25.7)	63 (22.9)		114 (31.7)	179 (24.3)
Unadjusted		Ref.	0.623 (0.429-0.906)	0.673 (0.466-0.973)	0.578 (0.396-0.843)	0.011	Ref.	0.681 (0.516-0.900)
Model 1		Ref.	0.652 (0.445-0.956)	0.710 (0.485-1.040)	0.598 (0.406-0.882)	0.021	Ref.	0.698 (0.523-0.931)
Model 2		Ref.	0.604 (0.404-0.903)	0.615 (0.410-0.924)	0.448 (0.292-0.687)	<0.001	Ref.	0.583 (0.426-0.798)
Model 3		Ref.	0.595 (0.397-0.892)	0.622 (0.413-0.937)	0.463 (0.299-0.715)	0.001	Ref.	0.596 (0.434-0.818)
UTI
n (%)	35 (3.2)	9 (3.3)	12 (4.4)	7 (2.5)	7 (2.5)		13 (3.6)	22 (3.0)
Unadjusted		Ref.	1.344 (0.557-3.243)	0.746 (0.274-2.033)	0.760 (0.279-2.072)	0.390	Ref.	0.824 (0.410-1.655)
Model 1		Ref.	1.161 (0.477-2.828)	0.575 (0.207-1.600)	0.618 (0.223-1.709)	0.209	Ref.	0.690 (0.338-1.407)
Model 2		Ref.	1.148 (0.462-2.849)	0.602 (0.211-1.719)	0.742 (0.255-2.160)	0.410	Ref.	0.756 (0.357-1.601)
Model 3		Ref.	1.140 (0.458-2.838)	0.594 (0.208-1.697)	0.700 (0.238-2.056)	0.353	Ref.	0.738 (0.347-1.570)
Anemia
n (%)	383 (34.9)	62 (22.9)	87 (32.0)	105 (37.5)	129 (46.9)		85 (23.6)	298 (40.4)
Unadjusted		Ref.	1.585 (1.083-2.321)	2.023 (1.393-2.936)	2.978 (2.059-4.309)	<0.001	Ref.	2.204 (1.659-2.929)
Model 1		Ref.	1.422 (0.963-2.099)	1.723 (1.173-2.530)	2.682 (1.837-3.917)	<0.001	Ref.	2.013 (1.503-2.695)
Model 2		Ref.	1.305 (0.862-1.977)	1.525 (1.009-2.307)	1.756 (1.165-2.647)	0.007	Ref.	1.542 (1.125-2.115)
Model 3		Ref.	1.271 (0.836-1.934)	1.498 (0.986-2.274)	1.662 (1.092-2.530)	0.017	Ref.	1.475 (1.070-2.031)
Hypoproteinemia
n (%)	403 (36.7)	74 (27.3)	94 (34.6)	113 (40.4)	122 (44.4)		101 (28.1)	302 (40.9)
Unadjusted		Ref.	1.406 (0.975-2.027)	1.801 (1.259-2.578)	2.123 (1.484-3.036)	<0.001	Ref.	1.753 (1.335-2.301)
Model 1		Ref.	1.317 (0.908-1.910)	1.578 (1.092-2.282)	1.924 (1.334-2.773)	<0.001	Ref.	1.591 (1.204-2.104)
Model 2		Ref.	1.216 (0.819-1.806)	1.383 (0.932-2.053)	1.237 (0.831-1.840)	0.344	Ref.	1.220 (0.902-1.650)
Model 3		Ref.	1.175 (0.789-1.750)	1.367 (0.917-2.036)	1.238 (0.825-1.859)	0.321	Ref.	1.198 (0.882-1.626)
Pneumonia
n (%)	380 (34.6)	85 (31.4)	83 (30.5)	105 (37.5)	107 (38.9)		110 (30.6)	270 (36.6)
Unadjusted		Ref.	0.961 (0.668-1.383)	1.313 (0.923-1.868)	1.394 (0.979-1.984)	0.025	Ref.	1.295 (0.989-1.694)
Model 1		Ref.	0.891 (0.614-1.293)	1.135 (0.788-1.636)	1.244 (0.865-1.789)	0.118	Ref.	1.161 (0.879-1.533)
Model 2		Ref.	0.820 (0.549-1.225)	1.021 (0.688-1.516)	0.972 (0.648-1.458)	0.854	Ref.	0.996 (0.733-1.354)
Model 3		Ref.	0.769 (0.512-1.157)	0.986 (0.659-1.474)	0.924 (0.607-1.407)	0.997	Ref.	0.950 (0.694-1.300)
DVT
n (%)	365 (33.2)	67 (24.7)	101 (37.1)	104 (37.1)	93 (33.8)		95 (26.4)	270 (36.6)
Unadjusted		Ref.	1.798 (1.243-2.603)	1.799 (1.246-2.598)	1.556 (1.072-2.258)	0.068	Ref.	1.587 (1.202-2.094)
Model 1		Ref.	1.523 (1.034-2.244)	1.281 (0.868-1.891)	1.183 (0.799-1.751)	0.803	Ref.	1.251 (0.933-1.677)
Model 2		Ref.	1.483 (0.993-2.214)	1.268 (0.846-1.901)	1.033 (0.680-1.569)	0.688	Ref.	1.174 (0.861-1.600)
Model 3		Ref.	1.484 (0.990-2.223)	1.310 (0.869-1.973)	1.082 (0.706-1.657)	0.891	Ref.	1.219 (0.890-1.670)
Electrolyte disturbance
n (%)	813 (74.0)	205 (75.6)	198 (72.8)	211 (75.4)	199 (72.4)		269 (74.7)	544 (73.7)
Unadjusted		Ref.	0.861 (0.586-1.266)	0.985 (0.668-1.452)	0.843 (0.575-1.237)	0.494	Ref.	0.943 (0.707-1.259)
Model 1		Ref.	0.787 (0.533-1.164)	0.851 (0.571-1.268)	0.750 (0.507-1.108)	0.213	Ref.	0.853 (0.634-1.146)
Model 2		Ref.	0.781 (0.523-1.168)	0.825 (0.545-1.248)	0.684 (0.449-1.040)	0.104	Ref.	0.815 (0.595-1.115)
Model 3		Ref.	0.778 (0.520-1.166)	0.835 (0.550-1.268)	0.684 (0.446-1.049)	0.114	Ref.	0.823 (0.599-1.129)
Disorders of lipoprotein metabolism
n (%)	278 (25.3)	91 (33.6)	78 (28.7)	60 (21.4)	49 (17.8)		117 (32.5)	161 (21.8)
Unadjusted		Ref.	0.795 (0.553-1.145)	0.539 (0.369-0.790)	0.429 (0.288-0.639)	<0.001	Ref.	0.583 (0.440-0.772)
Model 1		Ref.	0.772 (0.534-1.116)	0.505 (0.342-0.748)	0.406 (0.271-0.609)	<0.001	Ref.	0.558 (0.418-0.744)
Model 2		Ref.	0.829 (0.565-1.216)	0.545 (0.362-0.819)	0.514 (0.333-0.793)	<0.001	Ref.	0.650 (0.479-0.883)
Model 3		Ref.	0.866 (0.579-1.295)	0.577 (0.375-0.887)	0.580 (0.366-0.918)	0.009	Ref.	0.722 (0.523-0.997)
DCI
n (%)	303 (27.6)	63 (23.2)	66 (24.3)	94 (33.6)	80 (29.1)		82 (22.8)	221 (29.9)
Unadjusted		Ref.	1.058 (0.712-1.571)	1.669 (1.146-2.429)	1.354 (0.923-1.988)	0.055	Ref.	1.425 (1.065-1.908)
Model 1		Ref.	1.026 (0.689-1.528)	1.575 (1.074-2.312)	1.293 (0.876-1.908)	0.105	Ref.	1.362 (1.012-1.833)
Model 2		Ref.	0.980 (0.648-1.481)	1.573 (1.052-2.352)	1.091 (0.720-1.654)	0.490	Ref.	1.238 (0.904-1.696)
Model 3		Ref.	0.957 (0.632-1.449)	1.569 (1.047-2.353)	1.091 (0.714-1.666)	0.473	Ref.	1.229 (0.895-1.689)

ORs with 95% CIs were calculated using Logistic regression model.

Model 1: adjusted for age (continuous variable) and sex.

Model 3: adjusted for variables in model 2, plus preoperative WBC count, total cholesterol, triglyceride, high-density lipoprotein, and low-density lipoprotein.

Bold indicate statistical significance.

WFNS World Federation of Neurological Societies Scale; mFS modified Fisher Scale; WBC white blood cell; mRS modified Rankin Scale; WFNS World Federation of Neurological Societies Scale; mFS modified Fisher Scale; WBC white blood cell; mRS modified Rankin Scale; MACE major adverse cardiac event; UTI urinary tract infection; DVT deep venous thrombosis; DCI delayed cerebral ischemia;

No competing interests reported.

SupplementalTables.docx

Download PDF

Reviewers agreed at journal
04 Nov, 2024
Reviewers invited by journal
25 Sep, 2024
Editor assigned by journal
25 Sep, 2024
Editor invited by journal
09 Sep, 2024
Submission checks completed at journal
07 Sep, 2024
First submitted to journal
29 Aug, 2024

You are reading this latest preprint version

Relationship between De Ritis and clinical outcomes in patients with aneurysmal subarachnoid hemorrhage: Insights from the LongTEAM registry

Status:

Version 1

Abstract

Figures

Introduction

Methods

Results

Discussion

Conclusions

Declarations

References

Tables

Additional Declarations

Supplementary Files

Status:

Version 1